Investor Presentation - First Six Months of 2021
98
Investor presentation
First six months of 2021
Region China at a glance.
China
Million
250
Diabetes trend
DKK
billion
25
8%
21%
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
First half of 2021
Sales
(mDKK)
Growth²
GLP-1
100%
Total GLP-13
833
68%
200
20
20
80%
Long-acting insulin4
1,007
41%
I
Premix insulin5
2,668
10%
Insulin
150
53%¹
15
60%
Fast-acting insulin6
1,164
12%
212
100
197
10
163
50
Human insulin
1,360
(7%)
10
12%1
40%
Total insulin
6,199
10%
Other Diabetes care?
834
4%
5
20%
8%1
OAD
Diabetes care
7,866
13%
0
2019
0
0%
Obesity care (SaxendaⓇ)
16
325%
May
2030
2045
2016
May
2021
Biopharm³
170
(30%)
Population with diabetes
Diabetes growth rate
-GLP-1 MS
-Insulin MS
-OAD MS
Total
8,052
12%
Source: International Diabetes Federation: Diabetes Atlas 1th Edition 2000 and
Diabetes Atlas 9th Edition 2019
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of May 2021: Novo Nordisk 48%, Sanofi
18%, Gan & Lee 13% and Eli Lilly 9%; Competitor GLP-1 value market shares, as of
May 2021: Novo Nordisk 85% and AstraZeneca 3%
OAD: Oral anti-diabetic; MS: Market share; Source: IQVIA MAT, May 2021 value
figures
2 At constant exchange rates; 3 Comprises Victoza®: 4 Comprises TresibaⓇ
and LevemirⓇ: 5 Comprises NovoMix® and RyzodegⓇ: 6 Comprises
NovoRapidⓇ; 7 Comprises Novo NormⓇ and needles; 8 Comprises primarily
NovoSeven®, Novo Eight® and NorditropinⓇView entire presentation